Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CFO Michael Brian Bell sold 2,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the transaction, the chief financial officer directly owned 47,509 shares of the company's stock, valued at approximately $6,110,607.58. This trade represents a 4.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Michael Brian Bell also recently made the following trade(s):
- On Monday, March 16th, Michael Brian Bell sold 3,000 shares of Guardant Health stock. The stock was sold at an average price of $87.04, for a total value of $261,120.00.
Guardant Health Trading Down 0.6%
Shares of GH stock opened at $124.89 on Tuesday. The company has a market cap of $16.56 billion, a price-to-earnings ratio of -36.84 and a beta of 1.61. The stock has a 50 day simple moving average of $100.13 and a 200-day simple moving average of $101.32. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $134.28.
Wall Street Analyst Weigh In
GH has been the subject of a number of analyst reports. Wolfe Research initiated coverage on Guardant Health in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $150.00 target price for the company. Leerink Partners upped their price target on Guardant Health from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Friday, February 20th. Raymond James Financial restated an "outperform" rating and issued a $129.00 price target on shares of Guardant Health in a report on Monday, February 23rd. Barclays upped their price target on Guardant Health from $115.00 to $120.00 and gave the stock an "overweight" rating in a report on Friday, May 8th. Finally, TD Cowen restated a "buy" rating on shares of Guardant Health in a report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Guardant Health has a consensus rating of "Moderate Buy" and an average price target of $139.80.
View Our Latest Analysis on Guardant Health
Institutional Investors Weigh In On Guardant Health
A number of large investors have recently bought and sold shares of the stock. Allworth Financial LP grew its holdings in Guardant Health by 19.5% during the 3rd quarter. Allworth Financial LP now owns 844 shares of the company's stock valued at $53,000 after buying an additional 138 shares during the last quarter. Eastern Bank grew its holdings in Guardant Health by 6.9% during the 4th quarter. Eastern Bank now owns 2,160 shares of the company's stock valued at $221,000 after buying an additional 139 shares during the last quarter. First Pacific Financial grew its holdings in Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company's stock valued at $52,000 after buying an additional 139 shares during the last quarter. Xponance LLC grew its holdings in Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company's stock valued at $984,000 after buying an additional 199 shares during the last quarter. Finally, Danske Bank A S grew its holdings in Guardant Health by 20.0% during the 4th quarter. Danske Bank A S now owns 1,200 shares of the company's stock valued at $123,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
